Your browser is no longer supported. Please, upgrade your browser.
Settings
AXLA Axcella Health Inc. daily Stock Chart
AXLA [NASD]
Axcella Health Inc.
Index- P/E- EPS (ttm)-4.43 Insider Own0.30% Shs Outstand28.91M Perf Week-3.06%
Market Cap100.61M Forward P/E- EPS next Y-3.17 Insider Trans52.91% Shs Float21.76M Perf Month-9.14%
Income- PEG- EPS next Q-0.64 Inst Own62.50% Short Float0.20% Perf Quarter-48.52%
Sales- P/S- EPS this Y-16.60% Inst Trans0.34% Short Ratio1.41 Perf Half Y-68.25%
Book/sh3.22 P/B1.08 EPS next Y-9.70% ROA- Target Price14.33 Perf Year-
Cash/sh3.65 P/C0.95 EPS next 5Y- ROE- 52W Range2.76 - 15.99 Perf YTD-74.78%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-78.24% Beta-
Dividend %- Quick Ratio11.70 Sales past 5Y- Gross Margin- 52W Low26.09% ATR0.51
Employees64 Current Ratio11.70 Sales Q/Q- Oper. Margin- RSI (14)38.55 Volatility8.87% 13.77%
OptionableNo Debt/Eq0.33 EPS Q/Q65.00% Profit Margin- Rel Volume0.77 Prev Close3.55
ShortableYes LT Debt/Eq0.33 EarningsNov 11 Payout- Avg Volume30.76K Price3.48
Recom1.70 SMA20-6.82% SMA50-23.86% SMA200-54.86% Volume23,775 Change-1.97%
Jun-03-19Initiated SVB Leerink Outperform $21
Jun-03-19Initiated JP Morgan Overweight $20
Jun-03-19Initiated Goldman Buy $25
Dec-07-19 08:00AM  Axcella Presents Data at ASH Annual Meeting Business Wire
Dec-05-19 05:11AM  Trade Alert: The Chairman Of Axcella Health Inc. (NASDAQ:AXLA), David Epstein, Has Just Spent US$54k Buying Shares Simply Wall St.
Nov-25-19 08:00AM  Axcella Strengthens Executive Team with Key Addition and Promotion Business Wire
Nov-20-19 08:00AM  Axcella Announces Issuance of Broad Patent Covering EMM Compositions Business Wire +5.33%
Nov-12-19 04:05PM  Axcella Health Reports Third Quarter 2019 Financial Results and Provides Company Update Business Wire -6.40%
Nov-08-19 08:00AM  Axcella Presents Data at The Liver Meeting Providing New Mechanistic Insights on Observed Multifactorial Effects of its Liver Product Candidates Business Wire -5.46%
Nov-06-19 08:00AM  Axcella Achieves Initial Milestones with its Hematology Product Candidate AXA4010 Business Wire -13.56%
07:08AM  Need To Know: Axcella Health Inc. (NASDAQ:AXLA) Insiders Have Been Buying Shares Simply Wall St.
Oct-23-19 07:30AM  Axcella Enters into Collaboration with CYTOO to Explore Impact of Dysregulated Metabolism on Muscle Physiology Business Wire
Oct-11-19 05:49PM  Bay Area biotech unicorn suffers 5th worst Wall Street debut of year American City Business Journals
Oct-07-19 08:30AM  Axcella Provides Progress Updates for Liver Program Candidates AXA1125 and AXA1957 Business Wire
Oct-01-19 04:11PM  Axcella Announces Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting Business Wire -6.01%
Sep-03-19 05:45AM  The 4 Worst IPOs So Far This Year Barrons.com
Aug-23-19 04:27PM  Axcella Health Inc. Announces Appointment of Catherine A. Sohn, Pharm. D. to its Board of Directors Business Wire
Aug-12-19 05:06PM  Axcella Health Reports Second Quarter 2019 Financial Results and Provides Company Update Business Wire
Aug-08-19 10:48AM  What Type Of Shareholder Owns Axcella Health Inc.'s (NASDAQ:AXLA)? Simply Wall St.
Aug-07-19 05:54PM  Axcella to Present at the Wedbush PacGrow Healthcare Conference Business Wire
Jul-31-19 08:00AM  Axcella Announces Publication of Data Describing Attenuation of Muscle Atrophy with AXA2678 in Short-Term Muscle Disuse Study Business Wire
Jun-20-19 05:10PM  Axcella Health Reports First Quarter 2019 Financial Results and Provides Company Update GlobeNewswire
May-13-19 05:30PM  Axcella Health Announces Closing of Initial Public Offering GlobeNewswire
May-08-19 08:40PM  Axcella Health Announces Pricing of Initial Public Offering GlobeNewswire
07:11AM  Uber in drivers seat as IPO market gears up for busiest week since 2015 MarketWatch
May-06-19 06:08PM  The Axcella Health IPO: What You Need To Know Benzinga
May-04-19 05:25PM  IPO Outlook For The Week: Uber (And 11 Others) Benzinga
Axcella Health Inc., a biotechnology company, researches and develops novel multifactorial interventions to support health and address dysregulated metabolism in the United States. The company develops its products based on its AXA Development Platform. It offers AXA1665 for use in treating hepatic encephalopathy; AXA1125 and AXA1957 to treat non-alcoholic fatty liver disease; AXA2678 for use in treating immobilization-induced acute muscle atrophy; and AXA4010 to target multiple biological pathways. Axcella Health Inc. has a collaboration with CYTOO to explore impact of dysregulated metabolism on muscle physiology. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Epstein David RDirectorNov 27Buy3.911,0053,93053,298Dec 03 11:20 AM
Epstein David RDirectorNov 27Buy3.911,0053,93053,298Dec 02 07:31 PM
Epstein David RDirectorNov 26Buy3.5514,00049,70052,293Dec 03 11:20 AM
Epstein David RDirectorNov 26Buy3.5514,00049,70052,293Dec 02 07:31 PM